Drug Approval | August 27, 2024
Merck receives EC approval for Winrevair for treatment of PAH
Winrevair is the first activin signaling inhibitor therapy for PAH approved in Europe
Winrevair is the first activin signaling inhibitor therapy for PAH approved in Europe
The grant is designated for the research and development of Pyronaridine
PiaSky advances C5 inhibition through innovative recycling technology, which enables its monthly SC administration
New analyses, including presentations on mavacamten, apixaban and milvexian, further solidify the company's strength and expertise as a leader in cardiovascular diseases
Honeywell Quality Management Review helps manufacturers boost efficiency and quality compliance
This development will position the company at the forefront of anti- malaria API production globally and is expected to drive substantial growth and profitability
This addition highlights our commitment to meeting market needs and providing high-quality over the-counter solutions for our customers
Application based on the Transcend FL trial in which Breyanzi showed deep and durable responses and a consistent and well-established safety profile
Based on AEGEAN Phase III trial results which showed Imfinzi-based regimen reduced the risk of recurrence, progression or death by 32% vs. neoadjuvant chemotherapy alone
The robotic surgery program has continually pushed the boundaries of medical technology
Subscribe To Our Newsletter & Stay Updated
